Mr. Thomas Mehrling reports

HELIX BIOPHARMA RESPONDS TO MARKET ACTIVITY

Helix BioPharma Corp. wishes to confirm that it is not aware of any material, undisclosed information related to the company that would account for the recent increase in the market price and level of trading volume of its ordinary shares.

About Helix BioPharma Corp.

Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today's hardest-to-treat cancers. The company's pipeline is led by tumour defence breaker L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumours for increased sensitivity to therapy and augment the effectiveness of today's front-running anti-cancer treatments. L-DOS47 has completed phase 1b studies in non-small-cell lung cancer and shares its CEACAM6-targeting foundation with Helix's next-generation bispecific antibody-drug conjugates currently in discovery. The company also advances two preinvestigational new drug candidates: (i) Leumuna, an oral immune checkpoint modulator aimed at achieving durable remission in posttransplant leukemia relapse; and (ii) Gemceda, a first-in-class oral gemcitabine prodrug with bioavailability on a par with IV, designed to expand treatment options for advanced cancers.

We seek Safe Harbor.